and for three trials of neoadjuvant chemotherapy in high-risk localized prostate cancer patients. At the Dana–Farber Cancer Institute, from 2000 to 2009, Oh developed and managed a prospective clinical database linked to blood and tissue banks for more than 8,000 prostate cancer patients, with links to blood samples and tissue repositories, for exploration of research and prognostic applications, including: efficacy of various therapies in CRPC, hormonal therapy, testosterone as a marker for cancer outcome, relapse predictions based on nutritional factors at diagnosis and autoantibody signatures, and assessment of pharmacogenomic patterns predicting Gleason score. At Mount Sinai, he continued this work and developed a clinicogenomic database that resulted in multiple publications. Honors and awards 1992 Alpha Omega Alpha 1992 Prize in Internal Medicine, NYU School of Medicine 1997 ASCO/AACR Methods in Clinical Cancer Research Workshop 2003 Compassionate Caregiver of the Year, Kenneth B. Schwartz Center, Honorable Mention 2003–present, Best Doctors in America 2005 2009 Boston Magazine "Top Doctors" 2007–2008 Brigham/Harvard Business School Physician Leadership Program 2008–present, America's Top Doctors for Cancer (Castle Connolly) 2010 Prostate Cancer Foundation Creativity Award 2010–present, New York Magazine "Top Doctors" 2011 Election to the American Society of Clinical Investigation (ASCI) 2013 Fellow, American College of Physicians (FACP) Publications Partial list: References External links Mount Sinai Hospital homepage Icahn School of Medicine at Mount Sinai homepage Prostate Cancer Foundation homepage American oncologists Cancer researchers Icahn School of Medicine at Mount Sinai faculty Living people New York University Grossman School of Medicine alumni Yale University alumni Year of birth missing (living people)